186183-15-3

Upstream product

• 184427-37-0 N-((S)-1-(4-bromophenyl)-1-(ethoxycarbonyl)ethyl)-N'-(ethoxy-carbonylmethyl)urea 
• 184427-38-1 2-((S)-4-(4-bromophenyl)-4-methyl-2,5-dioxoimidazolidin-1-yl)acetic acid 
• 184427-34-7 (S)-2-amino-2-(4-bromophenyl)-propionic acid ethyl ester 
• 184426-81-1 2-((S)-4-(4-Cyanophenyl)-4-methyl-2,5-dioxoimidazolidin-1-yl)acetic acid 
• 340188-50-3 ethyl (S)-3-amino-3-phenyl-propionate hydrochloride 

Downstream Products

• 186183-13-1 Ethyl (S)-3-(2-((S)-4-(4-(amino-hydroximino-methyl)phenyl)-4-methyl-2,5-dioxoimidazolidin-1-yl)acetylamino)-3-phenylpropionate 
• 186183-13-1 (S)-3-(2-{(S)-4-[4-(N-Hydroxycarbamimidoyl)-phenyl]-4-methyl-2,5-dioxo-imidazolidin-1-yl}-acetylamino)-3-phenyl-propionic acid ethyl ester 

Relevant academic research and scientific papers

From Peptides to Heterocyclic Peptide Mimetics - Design and Synthesis of an Orally Active Fibrinogen Receptor Antagonist for the Prevention of Thrombosis

The binding of fibrinogen to the platelet fibrinogen receptor (GP IIb/IIIa receptor) depends on an Arg-Gly-Asp-Ser (RGDS) tetrapeptide recognition motif.Structural modifications of the RGDS tetrapeptide lead structure has led to the discovery of a non-peptide RGD mimetic GP IIb/IIIa antagonist 1 (S 1197).Compound 1 inhibited dose-dependently and reversibly human platelet aggregation.In conscious dogs the ethyl ester prodrug 2 (S 5740) showed a high plasma availability of the active moiety of 42+/-8percent (n=4) and a plasma half life of 9.9 hours after oral administration as measured by bioassay.Compound 2 may potentially be used for chronic treatment and prophylaxis of thrombotic diseases in humans.A pilot plant synthesis of compound 2 was developed.